Add BrightSurf on Google Email

Harvard Pilgrim Health Care Institute


Two PrEP medications are now available. Equally safe/effective. The biggest difference? The price tag.

A new study found that only 7% of patients who switched from Truvada to Descovy had a documented clinical reason for doing so, highlighting the need for cost-effective PrEP options. The significant price difference between the two medications may be a major barrier to broad and equitable PrEP use in the US.

SourceHarvard Pilgrim Health Care Institute·JournalOpen Forum Infectious Diseases·DateAug 5, 2021

Results of ABATE infection trial published

The ABATE Infection Trial found that daily antiseptic bathing with nasal ointment reduced hospital-acquired bloodstream infections by 30% in patients with central venous catheters, a high-risk group. This intervention also decreased antibiotic-resistant organisms, including MRSA and vancomycin-resistant enterococcus, in this patient po...

Providers' concerns about behavior change don't justify withholding HIV PrEP

Providers' reluctance to prescribe PrEP stems from concerns about increased risk-taking behavior among users. However, research suggests that PrEP can facilitate healthy sexual behaviors and enhance overall well-being. The authors propose strategies to mitigate biases and promote patient-centered care for PrEP dissemination.

SourceHarvard Pilgrim Health Care Institute·JournalNew England Journal of Medicine·DateFeb 6, 2019

Diabetes patients with high deductible health plans experience delays in seeking care

Research found that individuals with diabetes who switched to high-deductible health plans experienced delays in seeking care for symptoms of blood vessel diseases, including cardiac chest pain and transient ischemic attacks. The study suggests that increased out-of-pocket costs lead to changes in healthcare behavior.

SourceHarvard Pilgrim Health Care Institute·JournalAnnals of Internal Medicine·DateNov 19, 2018